Prevención de miopatías por estatinas, una revisión bibliográfica

Vista sencilla de ítem
dc.contributor.advisorCastillo Suarez, David German
dc.contributor.advisorVaca Alvarado, Leidy Johana
dc.contributor.authorSamper Garzón, Angy Carolina
dc.date.accessioned2024-05-15T19:19:18Z
dc.date.available2024-05-15T19:19:18Z
dc.date.issued2024-04
dc.description.abstractLas estatinas son fundamentales en el tratamiento de la dislipidemia y la prevención de enfermedades cardiovasculares, pero su uso puede verse limitado por la intolerancia o toxicidad. Entre estas complicaciones, las miopatías por estatinas varían en gravedad, desde mialgias leves hasta rabdomiólisis potencialmente fatal. Esta revisión bibliográfica realizó una exhaustiva búsqueda utilizando términos clave y bases de datos relevantes, siguiendo la metodología PRISMA. Se encontró que la prevalencia de miopatías por estatinas es baja, alrededor del 1%, pero la información disponible sobre este tema es limitada. La metodología de búsqueda incluyó la normalización de términos y la selección de artículos en español e inglés, con un límite temporal de 10 años. A pesar de la escasez de datos, se destaca la importancia de explorar alternativas para prevenir y tratar estas complicaciones, dada su significativa implicación en la seguridad y tolerabilidad del tratamiento con estatinas.
dc.description.abstractenglishStatins are essential in the treatment of dyslipidemia and the prevention of cardiovascular diseases, but their use may be limited by intolerance or toxicity. Among these complications, statin myopathies range in severity, from mild myalgias to potentially fatal rhabdomyolysis. This literature review carried out an exhaustive search using key terms and relevant databases, following the PRISMA methodology. The prevalence of statin myopathies was found to be low, around 1%, but the information available on this topic is limited. The search methodology included the standardization of terms and the selection of articles in Spanish and English, with a time limit of 10 years. Despite the scarcity of data, the importance of exploring alternatives to prevent and treat these complications is highlighted, given their significant implication in the safety and tolerability of statin treatment.
dc.description.degreelevelPregradospa
dc.description.degreelevelQuímico Farmacéuticospa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameUniversidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12123
dc.language.isoes
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programQuímica Farmacéuticaspa
dc.relation.referencesWorld Health Organization, "Cardiovascular diseases (CVDs)," [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
dc.relation.referencesF. D. Arias Rodríguez et al., "Diagnóstico y tratamiento de enfermedad vascular periférica. Revisión bibliográfica," *Angiología*, vol. 74, no. 6, pp. 292-304, ene. 23, 2023, doi: 10.20960/angiologia.00421.
dc.relation.referencesN. J. Stone et al., "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines," *Journal of the American College of Cardiology*, vol. 63, no. 25 Part B, pp. 2889-2934, 2014, doi: 10.1016/j.jacc.2013.11.002.
dc.relation.referencesJ. J. Kastelein y F. Akdim, "Statins: from plasma lowering to pleiotropy. Lessons from the heart," *European Journal of Preventive Cardiology*, vol. 23, no. 4, pp. 377-379, 2016, doi: 10.1177/2047487316641045.
dc.relation.referencesA. L. Zaleski, B. A. Taylor, y P. D. Thompson, "Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but…," *Advances in Nutrition*, vol. 9, no. 4, pp. 519S-523S, 2018, ISSN 2161-8313, doi: 10.1093/advances/nmy010.
dc.relation.referencesV. Mehta, R. Puri, P. B. Duell, et al., "Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid," *The Journal of the Association of Physicians of India*, vol. 70, no. 9, pp. 11-12, Sep. 2022, doi: 10.5005/japi-11001-0099.
dc.relation.referencesR. Cortés et al., "Miopatías metabólicas," *Revista Médica Clínica Las Condes*, vol. 29, no. 6, pp. 622-635, 2018, doi: 10.1016/j.rmclc.2018.09.004.
dc.relation.referencesA.R. Barry, J.E. Beach, and G.J. Pearson, "Prevention and management of statin adverse effects: A practical approach for pharmacists," *Can. Pharm. J.*, vol. 151, pp. 92-102, 2018. [Online]. Available: doi: 10.1177/1715163518768534
dc.relation.referencesR. Ariza Andraca, J. Halabe Cherem, and A. Lifshitz Guinzberg, "Intolerancia y miopatía por estatinas," *Scielo*, 2022. [Online]. Available: https://doi.org/10.35366/95407.
dc.relation.referencesP. Vinci, E. Panizon, L. M. Tosoni, C. Cerrato, F. Pellicori, F. Mearelli, C. Biasinutto, N. Fiotti, F. G. Di Girolamo, and G. Biolo, "Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy," *Scopus*, 2021. DOI: 10.3390/ijms222111687.
dc.relation.referencesJ. Millán, J. Pedro-Botet, E. Climent, J. Millán, and J. Rius, "Miopatía asociada al uso de estatinas en la práctica clínica. Resultados del estudio DAMA," *Elsevier*, 2017. DOI: 10.1016/j.arteri.2016.07.003.
dc.relation.referencesJ. M. Mostaza and C. Lahoz, "Main barriers in the management of dyslipidaemias: Intolerants," *Elsevier*, 2020. DOI: 10.1016/j.arteri.2020.12.003.
dc.relation.referencesOltion Mesi, MD, Charlie Lin, MD, Haitham Ahmed, MD, MPH and Leslie S. Cho, MD “ Statin intolerance and new lipid-lowering treatments” Cleveland Clinic Journal of Medicine July 2021, 88 (7) 381-387; DOI: https://doi.org/10.3949/ccjm.88a.20165
dc.relation.referencesG. Gheorghe, P. P. Toth, S. Bungau, T. Behl, M. Ilie, A. P. Stoian, O. G. Bratu, N. Bacalbasa, M. Rus, and C. C. Diaconu, "Cardiovascular Risk and Statin Therapy Considerations in Women," *Diagnostics*, vol. 10, no. 7, 2020, doi: 10.3390/diagnostics10070483.
dc.relation.referencesP. D. Thompson, G. Panza, A. Zaleski, and B. Taylor, "Statin-Associated Side Effects," *J. Am. Coll. Cardiol.*, vol. 67, no. 20, May 24, 2016, pp. 2395-2410, doi: 10.1016/j.jacc.2016.02.071.
dc.relation.referencesC. A. German and J. K. Liao, "Understanding the molecular mechanisms of statin pleiotropic effects," *Arch Toxicol*, vol. 97, no. 6, pp. 1529-1545, Jun. 2023, doi: 10.1007/s00204-023-03492-6.
dc.relation.referencesNewman, C.B., Preiss, D., Tobert, J.A., Jacobson, T.A., Page, R.L., Goldstein, L.B., Chin, C., Tannock, L.R., Miller, M., Raghuveer, G., Duell, P.B., Brinton, E.A., Pollak, A., Braun, L.T., Welty, F.K., (2019). "Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association." Arteriosclerosis, Thrombosis, and Vascular Biology 39. https://doi.org/10.1161/atv.0000000000000073.
dc.relation.referencesBair, T.L., May, H.T., Knowlton, K.U., Anderson, J.L., Lappe, D.L., Muhlestein, J.B. (2020). "Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study." J Cardiovasc Pharmacol, 75(5), 426-431. doi: 10.1097/FJC.0000000000000808.
dc.relation.referencesMargherita Bigossi, Cyrielle Maroteau, Adem Y Dawed, Alasdair Taylor, Sundararajan Srinivasan, Alaa’ Lufti Melhem, Ewan R Pearson, Roberto Pola, Colin N A Palmer, Moneeza K Siddiqui, A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 536–545, https://doi.org/10.1093/ehjcvp/pvad040
dc.relation.referencesBosco, G.; Di Giacomo Barbagallo, F.; Spampinato, S.; Lanzafame, L.; Di Pino, A.; Piro, S.; Purrello, F.; Scicali, R. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. J. Clin. Med. 2023, 12, 2444. https://doi.org/10.3390/jcm12062444
dc.relation.referencesNiedrig, D.F., Pyra, M., Lussmann, R., Serra, A., Russmann, S. (2023). "Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients." Eur J Hosp Pharm. doi: 10.1136/ejhpharm-2023-003765. Epub ahead of print. PMID: 37451842
dc.relation.referencesWarner M. Mampuya, David Frid, Michael Rocco, Julie Huang, Danielle M. Brennan, Stanley L. Hazen, Leslie Cho, "Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience," *American Heart Journal*, vol. 166, no. 3, pp. 597-603, 2013. DOI: 10.1016/j.ahj.2013.06.004.
dc.relation.referencesStroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. "Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management." *Eur Heart J*, vol. 36, no. 17, pp. 1012-1022, May 1, 2015. DOI: 10.1093/eurheartj/ehv043.
dc.relation.referencesRosenson RS, Baker S, Banach M, Borrow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD. "Optimizing Cholesterol Treatment in Patients With Muscle Complaints." *J Am Coll Cardiol*, vol. 70, no. 10, pp. 1290-1301, 2017. DOI: 10.1016/j.jacc.2017.07.752.
dc.relation.referencesJacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. "Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey." *J Clin Lipidol*, 2018. DOI: 10.1016/j.jacl.2017.09.006.
dc.relation.referencesIatan I, Mancini GBJ, Yeoh E, Hegele RA. "Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management." *Expert Rev Cardiovasc Ther* 2023;21:423–435. DOI: 10.1080/14779072.2023.2215982.
dc.relation.referencesPenson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A, Gaita D, Latkovskis G, Mazidi M, Toth PP, Pella D, Alnouri F, Postadzhiyan A, Yeh H, Mancini GBJ, Von Haehling S, Banach M. "Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)." *J Cachexia Sarcopenia Muscle* 2022;13:1596–1622. DOI: 10.1002/jcsm.12960.
dc.relation.referencesWard NC, Reid CM, Watts GF. "Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance." *Front Cardiovasc Med*. 2022. DOI: 10.3389/fcvm.2022.1060252.
dc.relation.referencesBallantyne, C.M., Banach, M., Mancini, G.B.J., Lepor, N.E., Hanselman, J.C., Zhao, X., Leiter, L.A. "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study." *Atherosclerosis*. 2018. DOI: 10.1016/j.atherosclerosis.2018.06.002.
dc.relation.referencesBanach, M., Penson, P.E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., Vrablik, M., Escobar, C. "Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)." *Progress in Cardiovascular Diseases*, vol. 79, 2023, pp. 2-11. ISSN 0033-0620, DOI: 10.1016/j.pcad.2023.03.001.
dc.relation.referencesKosmas, C.E., Pantou, D., Sourlas, A., Papakonstantinou, E.J., Echavarria Uceta, R., Guzman, E. "New and emerging lipid-modifying drugs to lower LDL cholesterol." *Drugs Context*, vol. 10, Nov. 2021, pp. 2021-8-3. DOI: 10.7573/dic.2021-8-3.
dc.relation.referencesA. Gupta y P. D. Thompson, "The relationship of vitamin D deficiency to statin myopathy," *Atherosclerosis*, vol. 215, no. 1, pp. 23–29, 2011, doi: 10.1016/j.atherosclerosis.2010.11.03.
dc.relation.referencesR. M. Papale y S. Schiaffino, "Manual de buenas prácticas de farmacovigilancia edición latinoamérica," 1a. ed. Ciudad Autónoma de Buenos Aires: Ediciones Farmacológicas, 2018. [Online]. Disponible en: [Archivo Digital: descarga y online]. ISBN 978-987-46704-2-7.
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2
dc.rights.localAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectEstatinas
dc.subjectMiopatías
dc.subjectDislípidemia
dc.subjectIntolerancia
dc.subjectRabdomiólisis
dc.subjectPrevención
dc.subject.ddc615.19
dc.subject.keywordsStatins
dc.subject.keywordsMyopathies
dc.subject.keywordsDyslipidemia
dc.subject.keywordsIntolerance
dc.subject.keywordsRhabdomyolysis
dc.subject.keywordsPrevention
dc.titlePrevención de miopatías por estatinas, una revisión bibliográfica
dc.title.translatedPrevention of myopathies by statins, a literature review
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Pregrado

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Trabajo de grado
Tamaño:
2.24 MB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Química Farmacéutica